1. Articles in category: Drug

    1-24 of 354 1 2 3 4 ... 13 14 15 »
    1. In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      J Control Release. 2018 Jul 03;285:162-171

      Authors: Yavuz B, Zeki J, Coburn JM, Ikegaki N, Levitin D, Kaplan DL, Chiu B

      Abstract High-risk neuroblastoma requires surgical resection and multi-drug chemotherapy. This study aimed to develop an extended release, implantable and degradable delivery system for etoposide, commonly used for neuroblastoma treatment.

      Read Full Article
    2. Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Conditions :   Childhood Solid Tumor;   Childhood Lymphoma Interventions :   Drug: Vinblastine;   Drug: Cyclophosphamide;   Drug: Capecitabine;   Drug: Nivolumab Sponsors :   Centre Oscar Lambret;   Anticancer Fund, Belgium;   Bristol-Myers Squibb Not yet recruiting

      Read Full Article
    3. Nanoparticles give immune cells a boost

      Nanoparticles give immune cells a boost

      ( Massachusetts Institute of Technology ) MIT researchers have devised a novel way to boost the effectiveness of T cell therapy against solid tumors. By attaching nanoparticle 'backpacks' carrying immune-stimulating drugs directly to T cells, the MIT engineers showed that they could enhance those T cells' response without inducing harmful side effects.

      Read Full Article
    4. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

      A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

      Novel druggable targets have been discovered in neuroblastoma (NB), paving the way for more effective treatments. However, children with high-risk NB still show high mortality rates prompting for a search of novel therapeutic options. Here, we aimed at repurposing FDA-approved drugs for NB treatment by performing a high-content screening of a 349 anticancer compounds library.

      Read Full Article
      Mentions: Treatment
    5. New study by MIT Sloan researchers provides insights on the challenges of developing drugs for pediatric cancer--and offers a potential solution

      New study by MIT Sloan researchers provides insights on the challenges of developing drugs for pediatric cancer--and offers a potential solution

      CAMBRIDGE, Mass., June 2, 2018 /PRNewswire-USNewswire/ -- Why is it so hard to develop drugs for children with cancer? And what can be done about it? Those questions are central to a new study published today in JAMA Oncology that explores new business models for funding drug...

      Read Full Article
      Mentions: COG
    6. Knockdown of zinc transporter ZIP8 expression inhibits neuroblastoma progression and metastasis in vitro.

      Knockdown of zinc transporter ZIP8 expression inhibits neuroblastoma progression and metastasis in vitro.

      Mol Med Rep. 2018 May 02;:

      Authors: Mei Z, Yan P, Wang Y, Liu S, He F

      Abstract Neuroblastoma is one of the leading causes of cancer‑associated mortality worldwide, particularly in children, partially due to the absence of effective therapeutic targets and diagnostic biomarkers.

      Read Full Article
    7. A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      Mol Cancer Ther. 2018 Apr 25;:

      Authors: Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L

      Read Full Article
    8. Dehydroeffusol inhibits viability and epithelial-mesenchymal transition through the Hedgehog and Akt/mTOR signaling pathways in neuroblastoma cells.

      Dehydroeffusol inhibits viability and epithelial-mesenchymal transition through the Hedgehog and Akt/mTOR signaling pathways in neuroblastoma cells.

      Eur J Pharmacol. 2018 Apr 14;:

      Authors: He K, Duan G, Li Y

      Abstract Neuroblastoma (NB) is the most predominant extracranial solid tumor of infancy in the world. However, current chemotherapy has limited efficacy for more advanced stages of NB due to acquired chemoresistance or acute toxicity in NB patients.

      Read Full Article
      Mentions: Chemotherapy
    9. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

      Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

      Future Oncol. 2018 Mar 29;:

      Authors: Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J

      Read Full Article
      Mentions: Refractory
    10. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

      Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

      Clin Cancer Res. 2018 Mar 07;:

      Authors: Nguyen F, Alferiev IS, Guan P, Guerrero DT, Kolla V, Moorthy GS, Chorny M, Brodeur GM

      Read Full Article
      Mentions: Nanoparticles
    11. Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

      Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

      Conditions :   Childhood Solid Tumor;   Childhood Lymphoma;   Relapsed Cancer;   Refractory Cancer;   Adult Solid Tumor;   Adult Lymphoma Interventions :   Drug: Pembrolizumab;   Drug: Decitabine;   Radiation: Hypofractionated Index Site Radiation Sponsor :   Children's Hospital Medical Center, Cincinnati Recruiting

      Read Full Article
    12. Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 26, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and other diseases, today announced that it received notification on Friday, February 23, 2018 that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to taurolidine for the treatment of neuroblastoma. Taurolidine is currently in preclinical development for neuroblastoma and is a key component in the Company's lead product, Neutrolin®, a novel anti-infective ...

      Read Full Article
      Mentions: Treatment
    13. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    1-24 of 354 1 2 3 4 ... 13 14 15 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles